ATE375794T1 - Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs - Google Patents
Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebsInfo
- Publication number
- ATE375794T1 ATE375794T1 AT01903785T AT01903785T ATE375794T1 AT E375794 T1 ATE375794 T1 AT E375794T1 AT 01903785 T AT01903785 T AT 01903785T AT 01903785 T AT01903785 T AT 01903785T AT E375794 T1 ATE375794 T1 AT E375794T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- cancer
- protein transferase
- transferase inhibitors
- farnesyl protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18455100P | 2000-02-24 | 2000-02-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE375794T1 true ATE375794T1 (de) | 2007-11-15 |
Family
ID=22677368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01903785T ATE375794T1 (de) | 2000-02-24 | 2001-02-20 | Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6838467B2 (de) |
| EP (1) | EP1267848B1 (de) |
| JP (1) | JP2003523381A (de) |
| AT (1) | ATE375794T1 (de) |
| AU (1) | AU2001231763A1 (de) |
| CA (1) | CA2397558A1 (de) |
| DE (1) | DE60130976T2 (de) |
| ES (1) | ES2293972T3 (de) |
| WO (1) | WO2001062234A2 (de) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1255537T1 (sl) * | 2000-02-04 | 2006-10-31 | Janssen Pharmaceutica Nv | Inhibitorji farnezil protein transferaze za zdravljenje raka dojk |
| JO2361B1 (en) * | 2000-06-22 | 2006-12-12 | جانسين فارماسيوتيكا ان. في | Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl |
| DE60230017D1 (de) * | 2001-02-15 | 2009-01-08 | Janssen Pharmaceutica Nv | Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen |
| CN1617755A (zh) * | 2001-11-30 | 2005-05-18 | 先灵公司 | 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用 |
| JP2007516258A (ja) | 2003-12-12 | 2007-06-21 | ワイス | 心臓血管の疾患治療に有用なキノリン誘導体 |
| NZ547277A (en) * | 2004-01-23 | 2009-08-28 | Janssen Pharmaceutica Nv | Substituted quinolines and their use as mycobacterial inhibitors |
| US20060106060A1 (en) * | 2004-03-18 | 2006-05-18 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies (Lansbury) |
| US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
| CA2559285A1 (en) * | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| WO2005089515A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| JP2007529555A (ja) * | 2004-03-18 | 2007-10-25 | ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド | シヌクレイノパチーを治療する方法 |
| WO2005089518A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Uch-l1 expression and cancer therapy |
| US20060194821A1 (en) * | 2005-02-18 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Compounds inhibiting the aggregation of superoxide dismutase-1 |
| EP2545919A1 (de) | 2005-12-23 | 2013-01-16 | Link Medicine Corporation | Behandlung von Synucleinopathien |
| CA2667363A1 (en) * | 2006-10-25 | 2008-05-02 | Schering Corporation | Discontinuous methods of treating cancer |
| US8232402B2 (en) * | 2008-03-12 | 2012-07-31 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
| US9561214B2 (en) * | 2008-10-16 | 2017-02-07 | Array Biopharma Inc. | Method of treatment using inhibitors of mitosis |
| US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
| CA2743717A1 (en) * | 2008-11-13 | 2010-05-20 | Link Medicine Corporation | Azaquinolinone derivatives and uses thereof |
| US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
| HK1213250A1 (zh) | 2012-10-16 | 2016-06-30 | Janssen Pharmaceutica, N.V. | RORγT的雜芳基連接的喹啉基調節劑 |
| ES2628365T3 (es) | 2012-10-16 | 2017-08-02 | Janssen Pharmaceutica N.V. | Moduladores de quinolinilo unidos a fenilo de ROR-GAMA-T |
| KR20150070347A (ko) | 2012-10-16 | 2015-06-24 | 얀센 파마슈티카 엔.브이. | Ror-감마-t의 메틸렌 결합 퀴놀리닐 조절제 |
| US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
| US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
| KR20160068956A (ko) | 2013-10-15 | 2016-06-15 | 얀센 파마슈티카 엔.브이. | RORyT의 퀴놀리닐 조절제 |
| AU2014334619A1 (en) | 2013-10-15 | 2016-04-21 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORyt |
| US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| DK3285768T3 (da) | 2015-04-21 | 2021-01-25 | Eiger Biopharmaceuticals Inc | Farmaceutiske sammensætninger omfattende lonafarnib og ritonavir |
| HUE057306T2 (hu) | 2015-08-17 | 2022-04-28 | Kura Oncology Inc | Módszerek rákos páciensek kezelésére farneziltranszferáz inhibitorokkal |
| US20190119758A1 (en) | 2016-04-22 | 2019-04-25 | Kura Oncology, Inc. | Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors |
| TW201818965A (zh) | 2016-11-03 | 2018-06-01 | 美商庫拉腫瘤技術股份有限公司 | 以法呢基轉移酶（ｆａｒｎｅｓｙｌ ｔｒａｎｓｆｅｒａｓｅ）抑制劑治療癌症病患之方法 |
| US10137121B2 (en) | 2017-02-21 | 2018-11-27 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
| EP3432883B1 (de) | 2017-02-21 | 2021-07-28 | Kura Oncology, Inc. | Verfahren zur behandlung von krebs mit farnesyltransferase-inhibitoren |
| TW201919628A (zh) | 2017-08-07 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 以法尼基轉移酶(farnesyltransferase)抑制劑治療癌症之方法 |
| US10806730B2 (en) | 2017-08-07 | 2020-10-20 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
| WO2019113269A1 (en) | 2017-12-08 | 2019-06-13 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
| CN113286591A (zh) | 2018-11-01 | 2021-08-20 | 库拉肿瘤学公司 | 用法尼基转移酶抑制剂治疗癌症的方法 |
| JP2022514654A (ja) | 2018-12-21 | 2022-02-14 | クラ オンコロジー， インコーポレイテッド | 扁平上皮癌のための治療法 |
| US20220142983A1 (en) | 2019-03-01 | 2022-05-12 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
| US20220143006A1 (en) | 2019-03-15 | 2022-05-12 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
| WO2020205486A1 (en) | 2019-03-29 | 2020-10-08 | Kura Oncology, Inc. | Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors |
| TW202102218A (zh) | 2019-04-01 | 2021-01-16 | 美商庫拉腫瘤技術股份有限公司 | 以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法 |
| US20220305001A1 (en) | 2019-05-02 | 2022-09-29 | Kura Oncology, Inc. | Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5686472A (en) | 1992-10-29 | 1997-11-11 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5834434A (en) * | 1993-05-18 | 1998-11-10 | University Of Pittsburgh | Inhibitors of farnesyltransferase |
| TW349948B (en) | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
| SI1162201T1 (sl) * | 1995-12-08 | 2006-08-31 | Janssen Pharmaceutica Nv | (Imidazol-5-il)metil-2-kinolinonski derivati kot inhibitorji farnezil protein transferaze |
| US5874442A (en) | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
| US6011029A (en) | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| WO1998028303A1 (en) | 1996-12-20 | 1998-07-02 | Tovarischestvo S Ogranichennoi Otvetstvennostju 'tabifarm' | METHOD AND DEVICE FOR PRODUCTION OF LYOPHILIZED HYDROCHLORIDE-1β,10β-EPOXY-13-DIMETHYLAMINO-GUAIA-3(4)-EN-6,12-OLIDE |
| TW591030B (en) | 1997-03-10 | 2004-06-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles |
| KR100520401B1 (ko) | 1997-04-25 | 2005-10-12 | 얀센 파마슈티카 엔.브이. | 파네실 트랜스퍼라제 억제작용을 갖는 퀴나졸리논 |
| US6303654B1 (en) | 1998-03-12 | 2001-10-16 | Wisconsin Alumni Research Foundation | Acyclic monoterpenoid derivatives |
| AU5086499A (en) | 1998-07-01 | 2000-01-24 | Merck & Co., Inc. | Process for making farnesyl-protein transferase inhibitors |
| AU4925199A (en) | 1998-08-27 | 2000-03-21 | Pfizer Products Inc. | Quinolin-2-one derivatives useful as anticancer agents |
| ES2259237T3 (es) | 1998-08-27 | 2006-09-16 | Pfizer Products Inc. | Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos. |
| EA004542B1 (ru) | 1998-12-23 | 2004-06-24 | Янссен Фармацевтика Н.В. | 1, 2-аннелированные производные хинолина |
-
2001
- 2001-02-20 EP EP01903785A patent/EP1267848B1/de not_active Expired - Lifetime
- 2001-02-20 AU AU2001231763A patent/AU2001231763A1/en not_active Abandoned
- 2001-02-20 ES ES01903785T patent/ES2293972T3/es not_active Expired - Lifetime
- 2001-02-20 US US10/220,162 patent/US6838467B2/en not_active Expired - Lifetime
- 2001-02-20 DE DE60130976T patent/DE60130976T2/de not_active Expired - Lifetime
- 2001-02-20 CA CA002397558A patent/CA2397558A1/en not_active Abandoned
- 2001-02-20 AT AT01903785T patent/ATE375794T1/de active
- 2001-02-20 WO PCT/EP2001/001937 patent/WO2001062234A2/en not_active Ceased
- 2001-02-20 JP JP2001561301A patent/JP2003523381A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001062234A2 (en) | 2001-08-30 |
| CA2397558A1 (en) | 2001-08-30 |
| US20030060450A1 (en) | 2003-03-27 |
| WO2001062234A8 (en) | 2001-09-27 |
| AU2001231763A1 (en) | 2001-09-03 |
| ES2293972T3 (es) | 2008-04-01 |
| DE60130976T2 (de) | 2008-07-17 |
| JP2003523381A (ja) | 2003-08-05 |
| EP1267848A1 (de) | 2003-01-02 |
| US6838467B2 (en) | 2005-01-04 |
| EP1267848B1 (de) | 2007-10-17 |
| DE60130976D1 (de) | 2007-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE375794T1 (de) | Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs | |
| DE60118889D1 (de) | Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs | |
| DE69815090D1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
| MY151032A (en) | Treatment of tnf? related disorders | |
| ATE253914T1 (de) | Farnesyl protein transferase inhibitoren zur behandlung von arthropathien | |
| ATE250932T1 (de) | Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer | |
| NO20052888L (no) | Diamintriazoler anvendelige som inhibitorer av proteinkinaser | |
| ATE298566T1 (de) | Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis | |
| ATE323490T1 (de) | Farnesyl-protein-transferasehemmer zur behandlung der entzündlichen darmerkrankung | |
| DE60105025D1 (de) | Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie | |
| ATE382346T1 (de) | Verfahren zur behandlung von krankheiten mit hsp90-hemmenden mitteln in kombination mit antimetaboliten | |
| NO20033665L (no) | Azoler som malonyl-CoA-dekarboksylaseinhibitorer som er anvendbare som metaboliske modulatorer | |
| ATE292801T1 (de) | Verfahren zum screening von inhibitoren von asp2 | |
| ATE360442T1 (de) | Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen | |
| ATE284224T1 (de) | Zusammensetzung enthaltend einen inhibitor der signaltransduktion von heterotrimerischen g- proteinen in kombination mit einem anderen anti- krebs mittel zu einer therapeutischen verwendung in der krebsbehandlung | |
| DE60329326D1 (de) | Tace inhibitoren | |
| DE60328772D1 (de) | Epothilonderivat zur behandlung von hepatoma und anderen krebserkrankungen | |
| TR200002203T2 (tr) | Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi. | |
| DE60231896D1 (de) | Zusammensetzungen und verfahren zur erhöhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus | |
| EA199901043A1 (ru) | ИНГИБИТОРЫ ФАРНЕЗИЛТРАНСФЕРАЗЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ HMG-CoA-РЕДУКТАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА | |
| DE60229047D1 (de) | Einzeldosis aromatase hemmer zur behandlung von unfruchtbarkeit | |
| HUP0300576A2 (hu) | Érkárosító hatású, osztott dózisú gyógyászati készítmény | |
| ATE516038T1 (de) | Metallcluster-nanoverbindungen zur behandlung von tumorerkrankungen | |
| DE602004022423D1 (de) | Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz | |
| DE60334289D1 (de) | Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen |